Symbols

ANTX

AN2 Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 3

Ample Liquidity

Price Hits New Low

Price Hits 52-week Low

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ANTX

An2 Therapeutics, Inc.

A biopharmaceutical company focused on developing treatments for infectious diseases and cancer

Industry

Pharmaceutical

Established Date

02/24/2017

Listing Date

03/25/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.an2therapeutics.com

Security Type

Common stock

Office address

1300 El Camino Real, Suite 100, Menlo Park, California 94025

Business

Introduction

AN2 Therapeutics, Inc., was incorporated in Delaware on February 24, 2017 and commenced operations in November 2019. The Company is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapies using its boron chemistry platform. Its R&D pipeline targets the fields of blood diseases, infectious diseases and oncology.

Company Financials

EPS

ANTX has released its 2025 Q4 earnings. EPS was reported at -0.29, versus the expected -0.24, missing expectations. The chart below visualizes how ANTX has performed over recent quarters, highlighting trends in earnings surprises.